Share on LinkedInShare on LinkedIn

ARTICLE · 08 MAY 2019

IPR Estoppel Applies Even After A Bench Trial On Validity

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

First, the district court held that estoppel applies even to prior-art references that were not raised in the IPR petitions.

United StatesIntellectual Property

In a recent decision, a district court in the District of Delaware applied estoppel under 35 U.S.C. § 315(e)(2) to a defendant in Hatch-Waxman litigation, two and half years after the court conducted a bench trial on validity. See Novartis Pharm. Corp. v. Par Pharm. Inc., No. 14-1289-RGA, ECF No. 198 (D. Del. Apr. 11, 2019) ("Slip Op.").

Between October 2014 and January 2015, Novartis filed three suits against Par for its submission of Abbreviated New Drug Applications ("ANDAs") seeking FDA approval of generic versions of Novartis's ZORTRESS® (everolimus) and AFINITOR® (everolimus) tablets. Novartis also sued Breckenridge and West-Ward for their ANDA filings relating to everolimus tablets. The defendants stipulated to infringement of the asserted U.S. Patent No. 5,665,772 ("the '772 patent"), but contested the validity of asserted claims 1-3, 7, and 10 in a four-day bench trial in late August and early September of 2016, raising invalidity challenges including

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from